Infleqtion Accelerates Quantum for Oncology as Q4Bio Challenge Enters Phase Three

Key Terms

biomarker discovery medical

Biomarker discovery is the process of finding measurable biological signals—like a specific molecule, gene pattern or protein—that indicate the presence, stage, or likely course of a disease or a patient’s response to a treatment. For investors it matters because validated biomarkers can speed drug development, reduce trial costs and unlock new diagnostics or companion products, similar to identifying a reliable fingerprint that lets a company target treatments more accurately and reach the market faster.

precision oncology medical

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

hybrid quantum–classical workflow technical

A hybrid quantum–classical workflow is a way of solving computing problems by splitting work between a quantum processor, which handles specialized, hard-to-solve pieces, and a regular (classical) computer, which manages the rest. Think of it as a kitchen where a chef uses a precision tool for delicate tasks and ordinary utensils for everything else. For investors, it matters because this mix can speed up certain calculations, influence development costs, and affect which companies gain a technical edge as quantum hardware matures.

quantum processors technical

Quantum processors are specialized computer chips that use the rules of quantum physics to process information with quantum bits (qubits), which can represent many possibilities at once rather than just 0 or 1. For investors, they matter because they promise drastically faster solutions for certain tasks—like searching databases, simulating materials, or optimizing complex systems—meaning companies that master or apply them could gain major technological and market advantages, but development is capital-intensive and risky.

Backed by Wellcome Leap program funding and selected to advance to final-stage demonstrations, Infleqtion moves forward with quantum-enabled biomarker discovery for precision oncology

LOUISVILLE, Colo.--(BUSINESS WIRE)-- Infleqtion, a global leader in quantum sensing and quantum computing powered by neutral-atom technology, announced that its quantum software team, together with collaborators at the University of Chicago (UChicago) and Massachusetts Institute of Technology (MIT), has been selected to advance to Phase 3 of the Wellcome Leap Quantum for Bio (Q4Bio) Challenge, a global program focused on demonstrating quantum-enabled solutions for human health. The news comes as Infleqtion prepares to go public through a merger with Churchill Capital Corp X (NASDAQ: CCCX).

“Phase 3 allows us to test quantum-enabled biomarker discovery end to end,” said Pranav Gokhale, CTO, Infleqtion. “We’re applying our hybrid quantum–classical workflow to real oncology data and evaluating whether quantum methods can improve feature selection on today’s hardware, not in simulations.”

Biomarker discovery, identifying molecular, genetic, or image-based features that help diagnose cancer, guide treatment, or predict patient response, requires analyzing high-dimensional, multimodal clinical datasets. Traditional tools often struggle to capture subtle or higher-order interactions across these data types. The Wellcome Leap Q4Bio program targets this challenge directly, supporting teams working to demonstrate quantum-enabled methods for human health within the next five years.

“This project only works because clinicians, biologists, and quantum scientists are designing the solution together,” added Gokhale. “That collaboration ensures the algorithms address genuine clinical needs while remaining implementable on near-term quantum hardware.”

Across Phases 1 and 2, the Infleqtion-led team built a hybrid quantum–classical workflow designed to handle the complexity of modern biomedical data. The approach combines organized preprocessing of DNA, RNA, and pathology image features with a higher-order optimization method that can capture interactions often missed by traditional techniques. The team also developed Hyper-RQAOA, a quantum routine tailored to current and near-term hardware that leverages parameter transfer techniques to greatly improve efficiency. Together, these components provide a practical way to test quantum-enabled feature selection on datasets that matter in real clinical settings.

Phase 3 transitions the effort from controlled simulations to experiments on real quantum processors. To succeed, teams must show meaningful performance on current devices and demonstrate how their methods will scale to the next generation of quantum systems. Infleqtion’s team will use this stage to tackle a more complex clinical question: forecasting treatment response in head-and-neck cancer using a curated cohort from UChicago. The goal is to determine whether quantum-in-the-loop analysis can reveal small, clinically useful biomarker sets that support precision oncology decisions.

Today’s announcement follows the release of the team’s flagship research paper, Toward Quantum-Enabled Biomarker Discovery: An Outlook from Q4Bio, now available on arXiv.

For more information, including technical details, publications, and collaboration opportunities, visit Infleqtion.com.

About Infleqtion

Infleqtion is a global leader in quantum sensing and quantum computing, powered by neutral-atom technology. Infleqtion designs and builds quantum computers, precision sensors, and quantum software for governments, enterprises, and research institutions. Infleqtion’s commercial portfolio includes quantum computers as well as quantum RF systems, quantum clocks, and inertial navigation solutions. Infleqtion is the partner of choice for governments and commercial customers seeking cutting-edge quantum capabilities. Infleqtion announced in September 2025 it plans to go public via a merger with Churchill X (NASDAQ: CCCX). For more information, visit Infleqtion.com or follow Infleqtion on LinkedIn, YouTube, and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205810320/en/

Matt Stubbs

Voxus PR

mstubbs@voxuspr.com

Source: Infleqtion